'Breakthrough' offers painless, instant liver test

A patient merely has to breathe into an instrument to determine whether he has hepatitis C or other infectious liver diseases.

May 15, 2006 20:48
1 minute read.
'Breakthrough' offers painless, instant liver test

breath test 88. (photo credit: )


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Painful liver biopsies - in which a long hollow needle is pressed into the abdomen to remove tissue samples to diagnose infectious disease - can be eliminated by a new "breakthrough" Israeli technology whose rights were acquired by Hadasit, the technology transfer company of the Hadassah Medical Organization. A patient merely has to breathe into an instrument to determine whether he has hepatitis C or other infectious liver diseases, Hadassah announced on Monday, with the results available in 40 minutes. The diagnostic device was developed by Oridion Systems Ltd., which has, together with Dr. Uri Geiger, set up a daughter company called Breath ID. This subsidiary will continue developing the instrument for the diagnosis of infectious liver diseases, enabling physicians throughout the world to enlarge the scope of diagnosing infectious liver diseases. Using the new methodology, 150 hepatitis C patients have so far been checked at Hadassah and another 300 outside of Israel. Leaders of the American Liver Society supported Hadasit's purchase and the creation of the new company and are participating as members of the Breath ID scientific advisory board. "I consider Hadasit's entry into technological and financial activities an integral part of our commitment to improving medicine," said Hadasit CEO Dr. Rafi Hofstein. "The establishment of Breath ID will allow us to advance the progress of diagnosing infectious liver diseases and may even reveal new ways of treating these diseases." "Hadasit's involvement marks another step in the natural continuum of its growth so far, building on the establishment of Hadasit Bio-Holdings Ltd., whose stock is traded on the Tel Aviv Stock Exchange, the construction of a biotech park on the Jerusalem Ein Kerem campus and the creation of numerous start-up companies in the biomedical and bioengineering fields."

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia


Cookie Settings